Bristol-Myers Squibb, GlascoSmithKline... maybe ou
Post# of 150997
(Total Views: 206)
Posted On: 03/15/2025 2:04:58 AM
Bristol-Myers Squibb, GlascoSmithKline... maybe our North Star is a EuroStar.
The political climate might very well be better on the other side of the pond.
From Google AI:
"In the biotech and pharmaceutical world, a Contingent Value Right (CVR) is a mechanism used in mergers and acquisitions to bridge valuation gaps, offering additional consideration to target company shareholders if specific future events, like regulatory approvals or sales milestones, are achieved."
Being called a "target company" kind of implies predatory behavior on the part of the acquiring company... Interesting that AI would use that phrase. Well, that's capitalism for ya!
On the other hand, reasonable people, on the cusp of making history, working out a deal with mutual and professional respect--and a massive pie to divide--well, that's capitalism too.
"Bridging valuation gaps"... I'd say that speaks to our situation--at least at some point in the partnership-buyout process. Whatever side of the pond we end up on.
Leronlimab could very well be the gift that keeps on giving.
--Sherlock57/peace out--
The political climate might very well be better on the other side of the pond.
From Google AI:
"In the biotech and pharmaceutical world, a Contingent Value Right (CVR) is a mechanism used in mergers and acquisitions to bridge valuation gaps, offering additional consideration to target company shareholders if specific future events, like regulatory approvals or sales milestones, are achieved."
Being called a "target company" kind of implies predatory behavior on the part of the acquiring company... Interesting that AI would use that phrase. Well, that's capitalism for ya!
On the other hand, reasonable people, on the cusp of making history, working out a deal with mutual and professional respect--and a massive pie to divide--well, that's capitalism too.
"Bridging valuation gaps"... I'd say that speaks to our situation--at least at some point in the partnership-buyout process. Whatever side of the pond we end up on.
Leronlimab could very well be the gift that keeps on giving.
--Sherlock57/peace out--
(2)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼